Uso de Antiplaquetarios en Infarto Cerebral

Abstract

Antiplatelets are among the most commonly used drugs to reduce the risk of cardiovascular events in patients with transient Ischemic Attack and cerebral infarction. In the primary prevention stage its use is limited, and this will depend on the cardiovascular risk measured by scales such as the Framingam risk scale. In secondary prevention they have already demonstrated their usefulness as monotherapy (aspirin or clopidogrel) or dual therapy especially in the acute stage of minor cerebral infarction (aspirin / clopidogrel for 21 days). Other lines of research include the combined use of aspirin with direct anticoagulants or triple therapies. In this review article we show the published evidence on the benefit of antiplatelets in the prevention of cerebral infarction.